Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis – EB01, a novel sPLA2 inhibitor, after FDA’s approval.
Edesa expects the first patient to be enrolled in the coming quarter following the manufacturing of its drug candidate, it said in a press release.
EB01 employs a novel mechanism of action against a common inflammation pathway, Edesa explains. Unlike steroids and other anti-inflammatory drugs, like ibuprofen, the topical treatment being developed by Edesa is intended to inhibit the inflammatory process at its inception rather than after inflammation has occurred. In two previous clinical studies, Edesa says that EB01 has demonstrated significant improvement of multiple symptoms in contact dermatitis patients.
Dr. Par Nijhawan, Chief Executive Officer of Edesa said: “The company is committed to rapidly advancing our clinical plans and remains on track to initiate our clinical study for EB01.”